Engages the entire IL-15 receptor complex (IL-15Rα/IL-2Rβγ);enhanced anti-tumor efficacy of human CD19 CAR-T in in vivo lymphoma model;ongoing phase I clinical trial of combined CD19 CAR-T and NKTR-255 for R/R B-cell malignancies. This evidence concerns the gene CD19 and lymphoma.